<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088111</url>
  </required_header>
  <id_info>
    <org_study_id>AH501</org_study_id>
    <secondary_id>HHSO100201100034C</secondary_id>
    <nct_id>NCT03088111</nct_id>
  </id_info>
  <brief_title>An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis</brief_title>
  <official_title>A Phase 4, Open Label Field Study to Evaluate the Clinical Benefit, Safety, and Pharmacokinetics of Anthim (Obiltoxaximab) When Used in the Treatment of Suspected, Probable, or Confirmed Cases of Inhalational Anthrax Due to B. Anthracis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elusys Therapeutics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eurofins</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Elusys Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This field study is a post-marketing requirement from the FDA to evaluate the clinical
      benefit (course of illness and survival), safety and pharmacokinetics of obiltoxaximab
      administered to patients as part of their medical care for treatment or prophylaxis of
      inhalational anthrax infection following exposure to Bacillus anthracis (B. anthracis). The
      protocol can be implemented for any individual who receives obiltoxaximab for a suspected,
      probable, or confirmed case of inhalational anthrax due to B. anthracis in the United States,
      including sporadic cases, small incidents and/or a mass event. In case of a small anthrax
      incident, to the extent possible, the information will be collected prospectively at
      prespecified time points, except where it would interfere with management of the subject's
      illness. However, because of the logistical complexities that would likely accompany a mass
      anthrax event, most data in this study are anticipated to be collected retrospectively. Both
      retrospective and prospective data collection are allowed to maximize information collection.
      This study will collect data on the use of obiltoxaximab in anthrax infected or exposed
      subjects and the data collected will inform the understanding of the clinical benefit and
      safety of obiltoxaximab.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival in suspected, probable, or confirmed cases of inhalational anthrax at Week 24</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Overall survival will be summarized by frequency of subjects who completed the study at Week 24, and subjects who died before that visit. Population survival distribution function (SDF) will be estimated using the Kaplan-Meier (KM) method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival at Day 14 and Day 28</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Population survival rates at 14 and 28 days will be estimated using the KM method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of survival (to Week 24)</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>The KM method will be used to estimate duration of survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression and associated complications rates of anthrax (meningitis, pleural effusion, ventilator support) (to Week 24)</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>The progression to systemic anthrax infection and complication rates will be summarized using KM estimates associated with time to disease progression and time to complication of anthrax. The population SDFs of time to progression to systemic anthrax infection and of time to complication will be estimated using the KM method. Summary statistics of subjects with disease progression and complication rates will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified SOFA score (to Week 24)</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Modified sequential organ failure assessment (SOFA) scores will be assessed using 5 organ systems (respiratory, liver, cardiovascular, central nervous system, renal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of B. anthracis bacteremia</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Incidence and duration of B. anthracis bacteremia will be summarized by total incidence across time points of subjects with bacteremia and time from study drug administration to onset of bacteremia.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infection, Bacterial</condition>
  <condition>Anthrax</condition>
  <arm_group>
    <arm_group_label>Obiltoxaximab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is an open label, 24-week, single arm field study that will be implemented for subjects who receive FDA-approved obiltoxaximab as part of their medical treatment for inhalational anthrax infection in the United States. Adult subjects will be administered a single, intravenous (IV) dose of 16 mg/kg obiltoxaximab given as part of their medical care. Children will receive a weight-adjusted dose.
The primary purpose of the study is to collect data from subjects who have been treated with obiltoxaximab as part of their medical care for inhalational anthrax and to collect additional blood samples for measurement of obiltoxaximab concentrations and presence of anti-therapeutic antibodies (ATA).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of samples</intervention_name>
    <description>To the extent possible, blood samples will be collected from all subjects prior to infusion and at specified time points post-infusion to determine serum obiltoxaximab concentrations and ATA titers. Scavenged blood samples can be utilized, if acceptable, to maximize sample analyses for pharmacokinetic and other investigational parameters. Data on other relevant laboratory testing will only be collected and evaluated if available in the subject's record (eg, protective antigen (PA), anti-PA, anti-lethal factor (LF), anti-edema factor, IgG antibodies, anthrax lethal toxin neutralizing activity, presence of anthrax LF, incidence and duration of B. anthracis bacteremia, and demonstration of B. anthracis antigens in tissues).</description>
    <arm_group_label>Obiltoxaximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Obiltoxaximab</intervention_name>
    <description>Obiltoxaximab standard of care</description>
    <arm_group_label>Obiltoxaximab</arm_group_label>
    <other_name>Anthim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women (including pregnant and lactating women) and children of all ages who
             receive obiltoxaximab as part of their clinical care for anthrax infection and are
             willing and able to give written informed consent themselves or through legally
             acceptable representative (for minors, unconscious adults or deceased subjects) to
             participate in the study

        Exclusion Criteria:

          -  There are no exclusion criteria defined for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christa Nagy, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Elusys Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy S. Leach, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Contract Medical Monitor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>: Angela Williamson</last_name>
    <phone>919-558-3660</phone>
    <email>angela.williamson@ppdi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steven Warthan</last_name>
    <phone>910-558-6759</phone>
    <email>steven.warthan@ppdi.com</email>
  </overall_contact_backup>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AnthimÂ®</keyword>
  <keyword>Obiltoxaximab</keyword>
  <keyword>anthrax</keyword>
  <keyword>anti-toxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anthrax</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Antitoxins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

